You are viewing an expired study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials

Newark, Delaware

  • Neoplasm Metastasis

Purpose:

The purpose of this study is to predict responses to Erbitux as a single agent in patients with Non Small Cell Lung Cancer


Criteria:

Inclusion Criteria: - Measurable disease tumor available for biopsies - Life expectancy of at least 3 months Exclusion Criteria: - Known or documented brain metastases prior to Cetuximab therapy


NCT ID:

NCT00207116


Primary Contact:

Study Director
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Eli Lilly and Company


Backup Contact:

N/A


Location Contact:

Newark, Delaware
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: April 03, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.